Loading…
Zhejiang maker of pharmaceutical intermediates and APIs, including anesthetic and other fine-chemical active ingredients.
Zhejiang maker of pharmaceutical intermediates and APIs, including anesthetic and other fine-chemical active ingredients.
In one line: A small Chinese API/CDMO supplier.
Moat: none (scale). Commodity API producer competing mainly on cost and regulatory filings.
Headquarters: Taizhou, Zhejiang, China · Employees: 2,736
Size Zhejiang Hisoar Pharmaceutical (002099.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.39B, the 1748th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥5.76 on 6 Nov 2026.
Performance Over six months the shares fell 9.2%, against -21.1% for the median peer and -16.4% for the China market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 9.2% over the last twelve months (peer median +17.6%); the operating margin is -12.7% (peer median 7.3%).
Valuation It trades at 4.9× enterprise value to sales against a peer median of 9.4× (8th cheapest of 19).
Capital Return on invested capital runs 5.9 points below its cost of capital (5.8% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.03B | CN¥1.85B | CN¥1.93B | CN¥2.14B | CN¥2.70B |
| Revenue growth | — | -4% | -10% | -21% | — |
| Gross profit | CN¥656M | CN¥378M | CN¥445M | CN¥192M | CN¥633M |
| EBITDA | n/a | CN¥228M | CN¥202M | CN¥88.9M | CN¥425M |
| Net income | -CN¥234M | -CN¥91.1M | -CN¥330M | -CN¥420M | CN¥88.0M |
| Free cash flow | -CN¥154M | -CN¥88.8M | CN¥53.2M | CN¥87.5M | -CN¥63.2M |
| Capital expenditure | CN¥90.2M | CN¥74.5M | CN¥122M | CN¥153M | CN¥179M |
| Total debt | CN¥1.53B | CN¥1.50B | CN¥1.51B | CN¥1.09B | CN¥1.35B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Hisoar Pharmaceutical 002099.SZ | $1.39B | -9% | +9% | -13% | 4.9× | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | $893M | -27% | +1% | 0% | 7.1× | n/a |
| Zhejiang Hisun Pharmaceutical 600267.SS | $2.32B | +18% | -7% | 15% | 1.8× | -9.1% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 8.8× | 14.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002099.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.3% | -7.0% | 9th highest of 21 |
| 6-month return | -9.2% | -21.1% | 7th highest of 21 |
| Distance from 52-week high | -36.6% | -43.7% | 9th highest of 21 |
| Revenue growth (TTM) | +9.2% | +17.6% | 8th lowest of 19 |
| Operating margin | -12.7% | 7.3% | 8th lowest of 19 |
| EV / Sales | 4.9× | 9.4× | 8th cheapest of 19 |
| ROIC minus cost of capital | -5.9 pp | -4.1 pp | 7th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | 4.9× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | 15.5× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 8.9× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 5.2× | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 2.4× | -15.4% | +3.9% |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 44.5× | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.37B | -32% | +21% | -127% | 15.3× | n/a | n/a |
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | 226.6× | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.43B | -30% | +12% | 19% | 0.9× | -17.5% | +7.0% |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 9.8× | 26.1% | +23.1% |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 1.4× | -7.4% | +12.7% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | 10.0× | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | 17.9× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 2.1× | 0.3% | -1.3% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | 10.7× | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 3.4× | -2.4% | +13.8% |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | 11.2× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 2.2× | 14.9% | +11.1% |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 3.9× | 31.6% | +16.6% |